About this trial
Research in acute care faces many challenges, including enrollment challenges, legal limitations in data sharing, limited funding, and lack of singular ownership of the domain of acute care. To overcome some of these challenges, the Center of Acute Care of the University Medical Center Groningen in the Netherlands, has established a de novo data-, image- and biobank named "Acutelines". Acutelines is initiated to improve recognition and treatment of acute diseases and obtain insight in the consequences of acute diseases, including factors predicting its outcome. Thereby, Acutelines contributes to development of personalized treatment and improves prediction of patient outcomes after an acute admission.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Triaged as one of highest two triage categories (red or orange) according to the Manchester triage system;
Triaged as the third highest triage category (yellow) and arrival by EMS of Helicopter Emergency Medical Service (HEMS;
Shock
Suspicion of sepsis (based on either physicians' suspicion, Sepsis-2 or Sepsis-3 criteria)
Disqualifiers
Referred for organ transplantation as recipient
Transfer from other hospital
Accidental contact patient material (i.e. internal work-related accident)
Trial population
Adult patients admitted to the emergency room for emergency medicine, internal medicine \[including sub-specializations as allergology, acute medicine, oncology, hematology, infectiology, nephrology, vascular medicine, geriatric medicine\], pulmonology, gastro-enterology and rheumatology.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Mortality (time and cause)
Mortality will be retrieved from the electronic health records (EHR) from the hospital and municipal registration. The cause of death will be retrieved from the EHR from the hospital, general practitioner and Dutch statistics' office (CBS).
Katz ADL-6 (functioning)
Katz ADL-6 (0-6, fully dependent-independent)
World Health Organization (WHO) performance status (functioning)
World Health Organization (WHO) performance status (0-4, normal performance-bedridden)
Karnofsky performance score (functioning)
Karnofsky performance score (10-100, moribund-normal performance)
Secondary outcomes
Biomarkers
Laboratory values (Hb \[mmol/L\], leukocytes \[/mL), trombocytes \[/ml\], creatinine \[mmol/L\], urea \[mmol/L\], CRP \[mg/L\], LDL cholesterol \[mmol/L\], HDL cholesterol \[mmol/L\], total cholesterol \[mmol/L\], AST \[U/L\], ALT \[U/L\], gGT \[U/L\], AF \[U/L\], bilirubin \[microl/L\], NTproBNP \[pg/mL\], troponin \[microg/L\]) will be retrieved from the electronic health records (EHR) from the hospital, general practitioner and pharmacy.
Medication use
Medication use will be retrieved from the electronic health records (EHR) from the hospital, general practitioner and pharmacy.
Treatment (non-pharmacological, including organ support)
Treatment (non-pharmacological) will be retrieved from the electronic health records (EHR) from the hospital, general practitioner and (helicopter) emergency medical service. Data will include intravenous fluid resuscitation, vasopressors, mechanical ventilation/non-invasive ventilation, oxygen supply, acute dialysis and extra-corporeal membrane oxygenation (ECMO)
Sequential organ failure assessment (SOFA)
SOFA scores will be available for patients admitted because of an infection.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.